ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT07217015

Public ClinicalTrials.gov record NCT07217015. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 24, 2026, 12:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Study identification

NCT ID
NCT07217015
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Enrollment
200 participants

Conditions and interventions

Interventions

  • KT-621 Drug
  • Placebo Other

Drug · Other

Eligibility (public fields only)

Age range
12 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 23, 2025
Primary completion
May 31, 2027
Completion
May 31, 2028
Last update posted
Apr 22, 2026

2025 – 2028

United States locations

U.S. sites
20
U.S. states
12
U.S. cities
17
Facility City State ZIP Site status
Kymera Investigative Site Birmingham Alabama 35244 Recruiting
Kymera Investigative Site North Little Rock Arkansas 72117 Recruiting
Kymera Investigative Site Freemont California 94538 Recruiting
Kymera Investigative Site Los Angeles California 90025 Recruiting
Kymera Investigative Site Los Angeles California 90045 Recruiting
Kymera Investigative Site Santa Monica California 91350 Recruiting
Kymera Investigative Site Delray Beach Florida 33484 Recruiting
Kymera Investigative Site Miami Florida 33137 Recruiting
Kymera Investigative Site Miramar Florida 33027 Recruiting
Kymera Investigative Site Normal Illinois 61761 Recruiting
Kymera Investigative Site Indianapolis Indiana 46202 Recruiting
Kymera Investigative Site Ann Arbor Michigan 48103 Recruiting
Kymera Investigative Site Detroit Michigan 48202 Recruiting
Kymera Investigative Site The Bronx New York 10455 Recruiting
Kymera Investigative Site Fargo North Dakota 58103 Recruiting
Kymera Investigative Site Portland Oregon 97201 Recruiting
Kymera Investigative Site Portland Oregon 97239 Recruiting
Kymera Investigative Site Philadelphia Pennsylvania 19103 Recruiting
Kymera Investigative Site San Antonio Texas 78213 Recruiting
Kymera Investigative Site San Antonio Texas 78218 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07217015, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 22, 2026 · Synced Apr 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07217015 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →